

Antonio Lacquaniti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7997542/publications.pdf>

Version: 2024-02-01

99
papers

3,098
citations

186265

28
h-index

168389

53
g-index

101
all docs

101
docs citations

101
times ranked

4512
citing authors

#	ARTICLE	IF	CITATIONS
1	Fabry disease and kidney involvement: starting from childhood to understand the future. <i>Pediatric Nephrology</i> , 2022, 37, 95-103.	1.7	13
2	Response to: Urine bikunin and kidney involvement in Fabry disease. <i>Pediatric Nephrology</i> , 2022, , 1.	1.7	0
3	Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin. <i>Journal of Clinical Medicine</i> , 2022, 11, 3759.	2.4	29
4	Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy. <i>Seminars in Dialysis</i> , 2021, 34, 183-195.	1.3	10
5	HMGB-1 and TGF β -1 highlight immuno-inflammatory and fibrotic processes before proteinuria onset in pediatric patients with Alport syndrome. <i>Journal of Nephrology</i> , 2021, 34, 1915-1924.	2.0	10
6	Acute and chronic kidney disease after pediatric liver transplantation: An underestimated problem. <i>Clinical Transplantation</i> , 2020, 34, e14082.	1.6	8
7	Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. <i>Kidney Research and Clinical Practice</i> , 2020, 39, 334-343.	2.2	8
8	Erythropoiesis and chronic kidney disease-related anemia: From physiology to new therapeutic advancements. <i>Medicinal Research Reviews</i> , 2019, 39, 427-460.	10.5	24
9	Non-Invasive Imaging for Evaluating Cardiovascular Involvement in Patients with Primary and Lupus Nephritis. <i>Open Rheumatology Journal</i> , 2019, 13, 86-93.	0.2	1
10	The Myth of Water and Salt: From Aquaretics to Tenapanor. , 2018, 28, 73-82.		8
11	Convective Dialysis Reduces Mortality Risk: Results From a Large Observational, Population-Based Analysis. <i>Therapeutic Apheresis and Dialysis</i> , 2018, 22, 457-468.	0.9	6
12	Opposite actions of urotensin II and relaxin on cellular expression of fibronectin in renal fibrosis: A preliminary experimental study. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 1069-1071.	1.9	2
13	Higher serum sclerostin levels and insufficiency of vitamin D are strongly associated with vertebral fractures in hemodialysis patients: a case control study. <i>Osteoporosis International</i> , 2017, 28, 577-584.	3.1	13
14	Renoprotective effect of erythropoietin in zebrafish after administration of gentamicin: an immunohistochemical study for β -catenin and c-kit expression. <i>Journal of Nephrology</i> , 2017, 30, 385-391.	2.0	5
15	Persistent Left Superior Vena Cava and Partially Left Inferior Vena Cava: A Case Report of a Dangerous Central Venous Catheterization. <i>Journal of Vascular Access</i> , 2017, 18, e66-e69.	0.9	7
16	Renal biopsy: Still a landmark for the nephrologist. <i>World Journal of Nephrology</i> , 2016, 5, 321.	2.0	37
17	New options for the management of polycystic kidney disease. <i>Giornale De Tecniche Nefrologiche & Dialitiche</i> , 2016, 28, 143-152.	0.1	1
18	MP555SALT WATER DISEQUILIBRIUM AND FLUID OVERLOAD IN HEMODYALYSES PATIENTS: A CENTRAL ROLE OF CORIN. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i525-i525.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. International Journal of Nephrology and Renovascular Disease, 2016, 9, 11.	1.8	25
20	SP266PREDICTING PROGRESSION IN CKD: CORIN BALANCES HEART AND RENAL SYSTEMS. Nephrology Dialysis Transplantation, 2016, 31, i176-i176.	0.7	0
21	Sclerostin levels in uremic patients: a link between bone and vascular disease. Renal Failure, 2016, 38, 759-764.	2.1	17
22	Delayed graft function and chronic allograft nephropathy: diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin. Biomarkers, 2016, 21, 371-378.	1.9	18
23	Metformin-related lactic acidosis: is it a myth or an underestimated reality?. Renal Failure, 2016, 38, 1560-1565.	2.1	29
24	Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. Journal of Clinical and Translational Endocrinology, 2016, 6, 8-14.	1.4	34
25	High mobility group box 1 and tumor growth factor β_2 : useful biomarkers in pediatric patients receiving peritoneal dialysis. Renal Failure, 2016, 38, 1370-1376.	2.1	10
26	3 Tesla-Diffusion Tensor Imaging in Autosomal Dominant Polycystic Kidney Disease: The Nephrologist's Point of View. Nephron, 2016, 134, 73-80.	1.8	10
27	Apelin and Copeptin as Biomarkers of Kidney Disease. , 2016, , 535-556.		0
28	Kidney-lung connections in acute and chronic diseases: current perspectives. Journal of Nephrology, 2016, 29, 341-348.	2.0	27
29	Kidney disease and psoriasis: novel evidences beyond old concepts. Clinical Rheumatology, 2016, 35, 297-302.	2.2	25
30	Salt-water imbalance and fluid overload in hemodialysis patients: a pivotal role of corin. Clinical and Experimental Medicine, 2016, 16, 443-449.	3.6	6
31	Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease. Current Medicinal Chemistry, 2016, 23, 1698-1707.	2.4	7
32	Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology. , 2016, , 205-227.		0
33	Thalassaemia major and infectious risk: High Mobility Group Box 1 represents a novel diagnostic and prognostic biomarker. British Journal of Haematology, 2015, 171, 130-136.	2.5	4
34	New available biomarkers to face a worldwide emergency: The childhood obesity. Journal of Pediatric Biochemistry, 2015, 04, 139-143.	0.2	0
35	Semaphorin 3A serum levels are influenced by haemodialysis: What clinical significance?. Nephrology, 2015, 20, 236-242.	1.6	1
36	Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment. Therapeutic Apheresis and Dialysis, 2015, 19, 471-476.	0.9	11

#	ARTICLE	IF	CITATIONS
37	Pseudotumor Cerebri Syndrome and Renal Diseases in the Pediatric Population. <i>Journal of Pediatric Neurology</i> , 2015, 13, 042-045.	0.2	3
38	Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* <scp>MRI</scp> assessment. <i>European Journal of Haematology</i> , 2015, 94, 404-412.	2.2	43
39	Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 368.e1-368.e9.	6.0	30
40	Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation. <i>Clinical and Experimental Medicine</i> , 2015, 15, 97-105.	3.6	37
41	Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology. , 2015, , 1-24.		0
42	Apelin and Copeptin as Biomarkers of Kidney Disease. , 2015, , 1-22.		0
43	Vitamin D intoxication in two brothers: be careful with dietary supplements. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2014, 27, 763-7.	0.9	21
44	Proteinuric effect of transcranial magnetic stimulation in healthy subjects and diabetic patients with Stage 3-4 CKD. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 573-579.	0.7	4
45	Emerging markers of cachexia predict survival in cancer patients. <i>BMC Cancer</i> , 2014, 14, 828.	2.6	44
46	From Water to Aquaretics: a Legendary Route. <i>Cellular Physiology and Biochemistry</i> , 2014, 33, 1369-1388.	1.6	12
47	Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein. <i>Medicinal Research Reviews</i> , 2014, 34, 77-105.	10.5	46
48	The future of phosphate binders: a perspective on novel therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1459-1463.	4.1	15
49	High-mobility group box 1 (HMGB1) in childhood: from bench to bedside. <i>European Journal of Pediatrics</i> , 2014, 173, 1123-1136.	2.7	34
50	LMNA gene mutation as a model of cardiometabolic dysfunction: From genetic analysis to treatment response. <i>Diabetes and Metabolism</i> , 2014, 40, 224-228.	2.9	9
51	Serum levels of Apelin-36 are decreased in older hospitalized patients with heart failure. <i>European Geriatric Medicine</i> , 2014, 5, 242-245.	2.8	5
52	Does Erythropoietin Always Win?. <i>Current Medicinal Chemistry</i> , 2014, 21, 849-854.	2.4	11
53	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Endothelial Progenitor Cells (EPCs) Evaluation in Aortic Aneurysm Repair. <i>Current Vascular Pharmacology</i> , 2014, 11, 1001-1010.	1.7	6
54	âœNormoalbuminuricâœdiabetic nephropathy: tubular damage and NGAL. <i>Acta Diabetologica</i> , 2013, 50, 935-942.	2.5	69

#	ARTICLE	IF	CITATIONS
55	Apelin and copeptin: Two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease. <i>Peptides</i> , 2013, 49, 1-8.	2.4	33
56	High-mobility group protein B1: a new biomarker of metabolic syndrome in obese children. <i>European Journal of Endocrinology</i> , 2013, 168, 631-638.	3.7	60
57	Prolactin in obese children: a bridge between inflammation and metabolic endocrine dysfunction. <i>Clinical Endocrinology</i> , 2013, 79, 537-544.	2.4	48
58	Can Neutrophil Gelatinase-associated Lipocalin Help Depict Early Contrast Material-induced Nephropathy?. <i>Radiology</i> , 2013, 267, 86-93.	7.3	43
59	Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. <i>European Journal of Endocrinology</i> , 2013, 169, 785-793.	3.7	27
60	Impact of diabetes on cognitive impairment and disability in elderly hospitalized patients with heart failure. <i>Geriatrics and Gerontology International</i> , 2013, 13, 1035-1042.	1.5	13
61	Neutrophil gelatinase-associated lipocalin in peritoneal dialysis reflects status of peritoneum. <i>Journal of Nephrology</i> , 2013, 26, 1151-1159.	2.0	7
62	Before and After Preeclampsia: What Biomarkers are there?. <i>Current Women's Health Reviews</i> , 2013, 8, 269-275.	0.2	0
63	Modifications in relaxin's serum levels during acetate-free biofiltration (AFB): only a new biomarker?. <i>Italian Journal of Anatomy and Embryology</i> , 2013, 118, 98-9.	0.1	3
64	Hydrocarbons and Kidney Damage: Potential Use of Neutrophil Gelatinase-Associated Lipocalin and Sister Chromatide Exchange. <i>American Journal of Nephrology</i> , 2012, 35, 271-278.	3.1	13
65	Real-time monitoring of breath ammonia during haemodialysis: use of ion mobility spectrometry (IMS) and cavity ring-down spectroscopy (CRDS) techniques. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2945-2952.	0.7	59
66	A Biotechnological T-Shirt Monitors the Patient's Heart during Hemodialysis. <i>Renal Failure</i> , 2012, 34, 818-820.	2.1	0
67	NGAL as an Early Biomarker of Kidney Disease in Joubert Syndrome: Three Brothers Compared. <i>Renal Failure</i> , 2012, 34, 495-498.	2.1	14
68	Apelin, Plasmatic Osmolality and Hypotension in Dialyzed Patients. <i>Blood Purification</i> , 2012, 33, 317-323.	1.8	20
69	Fibrosis, regeneration and cancer: what is the link?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 21-27.	0.7	29
70	NGAL is a Precocious Marker of Therapeutic Response. <i>Current Pharmaceutical Design</i> , 2011, 17, 844-849.	1.9	15
71	From chronic kidney disease to transplantation: The roles of obestatin. <i>Regulatory Peptides</i> , 2011, 171, 48-52.	1.9	6
72	Levels of Neutrophil Gelatinase-Associated Lipocalin in 2 Patients With Crush Syndrome After a Mudslide. <i>American Journal of Critical Care</i> , 2011, 20, 405-409.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Obestatin: A New Element for Mineral Metabolism and Inflammation in Patients on Hemodialysis. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 104-110.	2.0	11
74	Obestatin: An Interesting but Controversial Gut Hormone. <i>Annals of Nutrition and Metabolism</i> , 2011, 59, 193-199.	1.9	53
75	Erythropoietin and the truths of science. <i>Journal of Nephrology</i> , 2011, 24, 564-568.	2.0	8
76	Neutrophil Gelatinase-Associated Lipocalin Levels in Patients With Crohn Disease Undergoing Treatment With Infliximab. <i>Journal of Investigative Medicine</i> , 2010, 58, 569-571.	1.6	38
77	From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. <i>European Journal of Clinical Investigation</i> , 2010, 40, 273-276.	3.4	86
78	Neutrophil gelatinase-associated lipocalin levels in chronic haemodialysis patients. <i>Nephrology</i> , 2010, 15, 23-26.	1.6	28
79	Alterations of Lipid Metabolism in Chronic Nephropathies: Mechanisms, Diagnosis and Treatment. <i>Kidney and Blood Pressure Research</i> , 2010, 33, 100-110.	2.0	32
80	Both IL-1 β and TNF- α Regulate NGAL Expression in Polymorphonuclear Granulocytes of Chronic Hemodialysis Patients. <i>Mediators of Inflammation</i> , 2010, 2010, 1-7.	3.0	12
81	Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: A new protein enters the scene. <i>Cancer Letters</i> , 2010, 288, 10-16.	7.2	150
82	Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 642-647.	1.6	19
83	Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. <i>Journal of Investigative Medicine</i> , 2010, 58, 569-71.	1.6	15
84	Genomic damage in endothelial progenitor cells from uremic patients in hemodialysis. <i>Journal of Nephrology</i> , 2010, 23, 328-34.	2.0	7
85	Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle?. <i>Medical Science Monitor</i> , 2010, 16, RA131-5.	1.1	28
86	Neutrophil gelatinase-associated lipocalin in the intensive care unit: Time to look beyond a single, threshold-based measurement?. <i>Critical Care Medicine</i> , 2009, 37, 2864.	0.9	0
87	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Progression of Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 337-344.	4.5	447
88	Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3398-3403.	0.7	41
89	The erythropoietin and regenerative medicine: a lesson from fish. <i>European Journal of Clinical Investigation</i> , 2009, 39, 993-999.	3.4	12
90	Perioperative Iloprost and Endothelial Progenitor Cells in Uremic Patients With Severe Limb Ischemia Undergoing Peripheral Revascularization. <i>Journal of Surgical Research</i> , 2009, 157, e129-e135.	1.6	18

#	ARTICLE	IF	CITATIONS
91	Malnutrition in the Elderly Patient on Dialysis. <i>Renal Failure</i> , 2009, 31, 239-245.	2.1	36
92	Neutrophil Gelatinase-Associated Lipocalin as an Early Biomarker of Nephropathy in Diabetic Patients. <i>Kidney and Blood Pressure Research</i> , 2009, 32, 91-98.	2.0	154
93	Neutrophil gelatinase-associated lipocalin in the intensive care unit: Time to look beyond a single, threshold-based measurement?. <i>Critical Care Medicine</i> , 2009, 37, 2864.	0.9	5
94	Regenerative Medicine: Does Erythropoietin have a Role?. <i>Current Pharmaceutical Design</i> , 2009, 15, 2026-2036.	1.9	17
95	Down with the Erythropoietin. Long Live the Erythropoietin !. <i>Current Drug Targets</i> , 2009, 10, 1028-1032.	2.1	12
96	Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Kidney Damage. <i>American Journal of Kidney Diseases</i> , 2008, 52, 595-605.	1.9	472
97	Pathological and Prognostic Value of Urinary Neutrophil Gelatinase-Associated Lipocalin in Macroproteinuric Patients with Worsening Renal Function. <i>Kidney and Blood Pressure Research</i> , 2008, 31, 274-279.	2.0	70
98	Neutrophil Gelatinase-Associated Lipocalin Reflects the Severity of Renal Impairment in Subjects Affected by Chronic Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2008, 31, 255-258.	2.0	103
99	Dialysis and the Elderly: An Underestimated Problem. <i>Kidney and Blood Pressure Research</i> , 2008, 31, 330-336.	2.0	32